**Highlights of This Issue**  5839

**SPECIAL FEATURES**

**CCR Translations**  5841

- Better Late than Early: FDG-PET Imaging in Metastatic Renal Cell Carcinoma
  Michael R. Harrison and Daniel J. George
  See article p. 6021

**Molecular Pathways**  5844

- Potential Prostate Cancer Drug Target: Bioactivation of Androstanediol by Conversion to Dihydrotestosterone
  James L. Mohler, Mark A. Titus, and Elizabeth M. Wilson

- ERK1/2 and p38α/β Signaling in Tumor Cell Quiescence: Opportunities to Control Dormant Residual Disease
  Maria Soledad Sosa, Alvaro Avivar-Valderas, Paloma Bragado, Huet-Chi Wen, and Julio A. Aguirre-Ghiso

**Review**  5858

- Thrombotic Microangiopathy with Targeted Cancer Agents
  John A. Blake-Haskins, Robert J. Lechleider, and Robert J. Kreitman

**HUMAN CANCER BIOLOGY**  5867

- Resection of Non–Small Cell Lung Cancers Reverses Tumor-Induced Gene Expression Changes in the Peripheral Immune System
  Andrew V. Kossenkov, Anil Vachani, Celia Chang, Calen Nichols, Shere Billouin, Wenhwa Horng, William N. Rom, Steven M. Alfelda, Michael K. Showe, and Louise C. Showe

**CANCER THERAPY: PRECLINICAL**  5901

- Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
  Xianbiao Xie, Markus P.H. Ghadimi, Eric D. Young, Roman Belousov, Quan-sheng Zhu, Juehui Liu, Gonzalo Lopez, Chiara Colombo, Tingsheng Peng, David Reynoso, Jason L. Hornick, Alexander J. Lazar, and Dina Lev

- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

- Killing of Resistant Cancer Cells with Low Bak by a Combination of an Antimesothelin Immunoconjugate and a TRAIL Receptor 2 Agonist Antibody
  Xing Du, Laiman Xiang, Crystal Mackall, and Ira Pastan

- Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
  Kelly M. Quesnelle and Jennifer R. Grandis
Targeting Human B-cell Malignancies through Ig Light Chain–Specific Cytotoxic T Lymphocytes
Jinsheng Weng, Soung-Chul Cha, Satoko Matsueda, Gheath Alatrash, Michael S. Popescu, Qing Yi, Jeffrey J. Molidrem, Michael Wang, Sattva S. Neelapu, and Larry W. Kwak

Curcumin Treatment Suppresses IKKb Kinase Activity of Salivary Cells of Patients with Head and Neck Cancer: A Pilot Study
Suejung G. Kim, Mysore S. Veena, Saroj K. Basak, Eugene Han, Tracey Tajima, David W. Gjertson, Joshua Starr, Ofer Eidelman, Harvey B. Pollard, Meera Srivastava, Eri S. Srivatsan, and Marilene B. Wang

Preclinical Pharmacokinetics and Safety of Sym004: A Synergistic Antibody Mixture Directed against Epidermal Growth Factor Receptor
Niels Jørgen Østergaard Skartved, Helle Jane Jacobsen, Mikkel Wandahl Pedersen, Pernille Foged Jensen, Jette Wagtberg Sen, Thomas Kjærsgaard Jørgensen, Adam Hey, and Michael Kragh

ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bel-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents
Cyrille Touzeau, Christelle Dousset, Linda Bodet, Patricia Gomez-Bougie, Stéphanie Bonnaud, Anne Moreau, Philippe Moreau, Catherine Pollat-Decesnynk, Martine Amiot, and Steven Le Gouill

IMAGING, DIAGNOSIS, PROGNOSIS

Automated Volumetric Growth Plate Measurement Using Magnetic Resonance Imaging for Monitoring Skeletal Toxicity in Children Treated on Investigational Drug Trials
AeRang Kim, Eva Dombi, Jeffrey Solomon, Elizabeth Fox, Frank M. Balis, and Brigitte C. Widemann

A Polymorphic –844T/C in FasL Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer
Wen-Wei Sung, Yao-Chen Wang, Ya-Wen Cheng, Ming-Ching Lee, Kun-Tu Yeh, John Wang, Chih-Yi Chen, and Huei Lee

Specific PET Imaging of xC− Transporter Activity Using a [18F]-Labeled Glutamate Derivative Reveals a Dominant Pathway in Tumor Metabolism

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
Irfan Kayani, Norbert Avril, Jasmed Bomanji, Simon Chowdhury, Andrea Rockall, Anju Sahdev, Paul Nathan, Peter Wilson, Jonathan Shamash, Kevin Sharpe, Louise Lim, John Dickson, Peter Ell, Andrew Reynolds, and Thomas Powles

Prognostic Impact of ΔTAp73 Isoform Levels and Their Target Genes in Colon Cancer Patients
Beatriz Soldevilla, Raquel Díaz, Javier Silva, Yolanda Campos-Marin, Concepción Muñoz, Vanesa García, José M García, Cristina Peña, Mercedes Herrera, Marta Rodríguez, Irene Gómez, Nagat Mohamed, Margarita M. Marques, Félix Bonilla, and Gemma Domínguez

Upregulation of Rac GTPase-Activating Protein 1 Is Significantly Associated with the Early Recurrence of Human Hepatocellular Carcinoma
Suk Mei Wang, London Lucien P.J. Ooi, and Kam M. Hui

CANCER THERAPY: CLINICAL

Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
Aung Naing, Razelle Kurzrock, Angelika Burger, Sachin Gupta, Xiudong Lei, Naifa Busaidy, David Hong, Helen X. Chen, Lawrence A. Doyle, Lance K. Heilbrun, Eric Rohren, Chaan Ng, Chandtip Chandhasin, and Patricia LoRusso
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing


Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors


Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer


Results of a Phase II Trial of Gemcitabine Plus Doxorubicin in Patients with Recurrent Head and Neck Cancers: Serum C18-Ceramide as a Novel Biomarker for Monitoring Response


ABOUT THE COVER

Interleukin-6 (IL-6) has tumor-promoting actions on both malignant and stromal cells in a range of experimental cancer models. In addition, high plasma IL-6 levels are associated with poor prognosis in ovarian cancer, but there is little information as to the source of this IL-6. Ovarian cancer biopsies were stained for IL-6 (left) and automated algorithms used to assess both malignant (right) and stromal (middle) compartments. Expression levels were quantified using an autoscore that combined both the intensity and density of positive pixels. IL-6 staining was seen in both the malignant and nonmalignant cells, but was significantly higher in the malignant cell areas. For further details, see Coward and colleagues on page 6083 of this issue.